Vyome Biosciences, of New Delhi, India, closed a $14 million series C financing round led by Perceptive Advisors and Romulus Capital along with participation from existing investors including Kalaari Capital, Sabre Partners and Aarin Capital. The company will use the funds predominantly to advance the clinical development of its lead product, VB 1953 for acne, while continuing to develop other products. Read More

The first half of 2016 is in the books, and while the biopharma sector's financial results weren't exactly a slam dunk, they did at least keep investors in the paint. As evidence of that, beginning with the closing bell on July 27, the Nasdaq Biotechnology Index has finished above 3,000 for the longest consecutive run since December 2015. Read More

SHANGHAI – KBP Biosciences (China) Inc. is the brainchild of Zhenhua Huang, a Chinese serial entrepreneur that first found success with his earlier effort, Xuanzhu Pharma. Huang is a rare breed of biotech founder, China-born and educated, he has an international vision for KBP building on the lessons learned from more than a decade of doing business in China. Read More

HONG KONG – With rapidly expanding on-the-ground operations, biotechnology giant Amgen Inc. is looking to strengthen its presence in Asian markets and to build more market share. Read More

PERTH, Australia – Drug manufacturers with operations in Australia will have four years to transition to new labeling requirements for medicines in Australia, long-awaited changes that may align with 21st century practices but, industry argued, likely won't solve the entire problem of medication errors. Read More

TOKYO – Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has issued a risk warning for filgrastim and a number of its derivatives after reports that it can lead to anaphylaxis. Read More